The effect of AUT00206, a Kv3 potassium channel modulator, on dopamine synthesis capacity and the reliability of [F]-FDOPA imaging in schizophrenia.

Background: Current treatments for schizophrenia act directly on dopamine (DA) receptors but are ineffective for many patients, highlighting the need to develop new treatment approaches. Striatal DA dysfunction, indexed using [F]-FDOPA imaging, is linked to the pathoetiology of schizophrenia. We evaluated the effect of a novel drug, AUT00206, a Kv3.